MedTrace Logo

Primary Liver Cancer Early Detection

NCT05996666 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 701

Last updated 2023-08-18

No results posted yet for this study

Summary

In the recently published multi-center, prospective, single-blind study (THUNDER study), using the methylation signal in cfDNA isolated from the peripheral blood to detect the six types of cancer, the sensitivity for liver cancer detection achieved 87.8%, with a specificity of 98.9%. In this study, a multicenter, case-control study is designed to establish an early cancer detection model based on cfDNA methylation biomarkers using qPCR to detect primary liver cancer and further validate the performance of the model.

Conditions

Interventions

DEVICE

Liver-cancer early detection test

Blood collection and liver-cancer early detection test

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • Tian Yang · Eastern Hepatobiliary Surgery Hospital

  • Nanya Wang · The First Hospital of Jilin University

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05996666 on ClinicalTrials.gov